Oncology Care Included in Medicare Disease Management Demonstrations

Publication
Article
OncologyONCOLOGY Vol 16 No 6
Volume 16
Issue 6

Oncology care will be the focus of one of the new Medicare disease management demonstration programs soon to be initiated. Medicare remains convinced that disease management services can provide substantial savings. There is, however, a problem: Fee-for-service Medicare, which includes most recipients, does not allow for disease management, except in one or two instances, such as diabetes self-education. The Medicare+Choice program-comprised mostly of health maintenance organizations-offers disease management, but seniors have, for the most part, avoided this plan. Therefore, Medicare has selected 15 sites for case management and disease management services, which will be offered to Medicare fee-for-service beneficiaries with complex chronic conditions. Quality Oncology, Inc, of McLean, Va, will implement an urban disease management program targeting beneficiaries in Broward County, Fla.

Oncology care will be the focus of one of the newMedicare disease management demonstration programs soon to be initiated.Medicare remains convinced that disease management services can provide substantialsavings. There is, however, a problem: Fee-for-service Medicare,which includes most recipients, does not allow for disease management, except inone or two instances, such as diabetes self-education. The Medicare+Choiceprogram—comprised mostly of health maintenance organizations—offers diseasemanagement, but seniors have, for the most part, avoided this plan. Therefore,Medicare has selected 15 sites for case management and disease managementservices, which will be offered to Medicare fee-for-service beneficiaries withcomplex chronic conditions. Quality Oncology, Inc, of McLean, Va, will implementan urban disease management program targeting beneficiaries in Broward County,Fla. 

The idea is for Quality Oncology to match the plan of care written by thepatient’s own oncologist. The Quality program’s medical director willcontact the patient’s oncologist to discuss any differences between the careplan and the guidelines. A care manager will provide patient education andcounseling, care coordination, and service arrangement.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.